Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group
The Bone group of the IMWG present recommendations for the use of whole body low-dose CT in patients with myeloma and other plasma cell disorders, as an imaging method for assessing bone disease in these patients.
Diagnostic techniques and prognostic indicators
Whole-Body MR Imaging: The Novel, “Intrinsically Hybrid,” Approach to Metastases, Myeloma, Lymphoma, in Bones and Beyond. Lecouvet FE et al. PET Clin. 2018 Oct. doi: 10.1016/j.cpet.2018.05.006. [Epub 2018 Aug 17] Role of oral examination in newly diagnosed multiple myeloma patients: A safe and simple way to detect light chain amyloidosis. Leiba M et al. Oral Dis. 2018 Oct. doi: 10.1111/odi.12901.…
Current treatments
Determining treatment intensity in elderly patients with multiple myeloma. Salvini M et al. Expert Rev Anticancer Ther. 2018 Sep. doi: 10.1080/14737140.2018.1496823. [Epub 2018 Jul 13] Treatment patterns and medication adherence among patients diagnosed with multiple myeloma and treated with panobinostat. Chari A et al. Future Oncol. 2018 Sep. doi: 10.2217/fon-2017-0727. [Epub 2018 May 30] Autologous stem cell transplantation in first…
General
The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets. Abramson HN. Clin Lymphoma Myeloma Leuk. 2018 Sep. doi: 10.1016/j.clml.2018.06.015. [Epub 2018 Jun 18] A new conceptual framework for the therapy by optimized multidimensional pulses of therapeutic activity. The case of multiple myeloma model. Horvath D and Brutovsky B. J Theor Biol. 2018 Oct 7. doi: 10.1016/j.jtbi.2018.06.015. [Epub 2018 Jun…
Biology and genetics
Bortezomib Targets Sp Transcription Factors in Cancer Cells. Karki Ket al. Mol Pharmacol. 2018 Oct. doi: 10.1124/mol.118.112797. [Epub 2018 Aug 16] IRF4 in multiple myeloma-Biology, disease and therapeutic target. Agnarelli A et al. Leuk Res. 2018 Sep. doi: 10.1016/j.leukres.2018.07.025. [Epub 2018 Aug 3] PGC1β regulates multiple myeloma tumor growth through LDHA-mediated glycolytic metabolism. Zhang H et al. Mol Oncol. 2018 Sep.…
Emerging treatments
Ixazomib: a novel drug for multiple myeloma. Zanwar S et al. Expert Rev Hematol. 2018 Sep 1. doi: 10.1080/17474086.2018.1518129. [Epub ahead of print] A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. San-Miguel JF et al. Haematologica. 2018 Sep. doi: 10.3324/haematol.2017.185991. [Epub 2018 Jun 28] Phase I study…
Complications of myeloma and its treatments
Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study. Cella D et al. Ann Hematol. 2018 Sep 4. doi: 10.1007/s00277-018-3469-4. [Epub ahead of print] Bilateral Angle Closure Following the Infusion of a Monoclonal Antibody to Treat Relapsing Multiple Myeloma. Lee AC et al. J…
General
Bone Health and Survival in Women With Multiple Myeloma.
Rosko AE et al. Clin Lymphoma Myeloma Leuk. 2018 Sep. doi: 10.1016/j.clml.2018.06.002. [Epub 2018 Jun 8]